Corcept Therapeutics Incorporated (CORT) Q1 2014 Earnings Results

Corcept Therapeutics Misses on EPS, Stock Down 50.5%

Corcept Therapeutics reported a loss per share of $0.11, which was slightly worse than expected. The stock reacted sharply, dropping 50.5% in response to the disappointing results and lack of guidance. Investors may be concerned about the company's future performance without clear direction from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.11	N/A	-6.80%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management's tone was defensive, reflecting the difficulties faced in the quarter. They did not offer any forward-looking guidance.

Management did not provide specific guidance for future quarters.

The company acknowledged challenges in meeting expectations.

Corcept Therapeutics Misses on EPS, Stock Down 50.5%

Key numbers

Management commentary

Corcept Therapeutics Incorporated

More earnings this week

Corcept Therapeutics Misses on EPS, Stock Down 50.5%

Key numbers

Management commentary